Cargando…

A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1

Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by es...

Descripción completa

Detalles Bibliográficos
Autores principales: Schön, Jacob, Ran, Wei, Gorka, Marco, Schwemmle, Martin, Beer, Martin, Hoffmann, Donata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229168/
https://www.ncbi.nlm.nih.gov/pubmed/32435514
http://dx.doi.org/10.1038/s41541-020-0185-6
_version_ 1783534705487904768
author Schön, Jacob
Ran, Wei
Gorka, Marco
Schwemmle, Martin
Beer, Martin
Hoffmann, Donata
author_facet Schön, Jacob
Ran, Wei
Gorka, Marco
Schwemmle, Martin
Beer, Martin
Hoffmann, Donata
author_sort Schön, Jacob
collection PubMed
description Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by establishing human-to-human transmissions. Besides culling measures in infected farms in endemic areas, vaccination is the major tool against HPAIV. However, the mainly used inactivated preparations have several limitations, like application to the individual animal by injection and a reduced efficiency. Here we present a modified live influenza vaccine prototype, which is based on the H17N10 bat influenza virus. The new chimeric vaccine strain R65(mono)/H17N10 was able to provide full protection against a lethal challenge infection with HPAIV H5N1 of juvenile and subadult chickens, as well as ferrets after oronasal immunization. In addition, the H5 vaccine prototype cannot reassort with avian influenza viruses and therefore is a promising tool against HPAIV H5 infection, allowing new vaccination strategies for efficient disease control.
format Online
Article
Text
id pubmed-7229168
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72291682020-05-20 A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1 Schön, Jacob Ran, Wei Gorka, Marco Schwemmle, Martin Beer, Martin Hoffmann, Donata NPJ Vaccines Article Highly pathogenic avian influenza viruses (HPAIVs) of subtype H5 are a major threat for poultry holdings worldwide, here especially the zoonotic Asian H5N1 viruses. These HPAIVs have caused more than 500 fatal spillover infections from poultry to humans, with a looming danger of a new pandemic by establishing human-to-human transmissions. Besides culling measures in infected farms in endemic areas, vaccination is the major tool against HPAIV. However, the mainly used inactivated preparations have several limitations, like application to the individual animal by injection and a reduced efficiency. Here we present a modified live influenza vaccine prototype, which is based on the H17N10 bat influenza virus. The new chimeric vaccine strain R65(mono)/H17N10 was able to provide full protection against a lethal challenge infection with HPAIV H5N1 of juvenile and subadult chickens, as well as ferrets after oronasal immunization. In addition, the H5 vaccine prototype cannot reassort with avian influenza viruses and therefore is a promising tool against HPAIV H5 infection, allowing new vaccination strategies for efficient disease control. Nature Publishing Group UK 2020-05-15 /pmc/articles/PMC7229168/ /pubmed/32435514 http://dx.doi.org/10.1038/s41541-020-0185-6 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Schön, Jacob
Ran, Wei
Gorka, Marco
Schwemmle, Martin
Beer, Martin
Hoffmann, Donata
A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
title A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
title_full A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
title_fullStr A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
title_full_unstemmed A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
title_short A modified live bat influenza A virus-based vaccine prototype provides full protection against HPAIV H5N1
title_sort modified live bat influenza a virus-based vaccine prototype provides full protection against hpaiv h5n1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229168/
https://www.ncbi.nlm.nih.gov/pubmed/32435514
http://dx.doi.org/10.1038/s41541-020-0185-6
work_keys_str_mv AT schonjacob amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT ranwei amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT gorkamarco amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT schwemmlemartin amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT beermartin amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT hoffmanndonata amodifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT schonjacob modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT ranwei modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT gorkamarco modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT schwemmlemartin modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT beermartin modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1
AT hoffmanndonata modifiedlivebatinfluenzaavirusbasedvaccineprototypeprovidesfullprotectionagainsthpaivh5n1